NCT05164744 Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
| NCT ID | NCT05164744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | COVID-19 Pneumonia |
| Study Type | OBSERVATIONAL |
| Enrollment | 510 participants |
| Start Date | 2021-07-01 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 510 participants in total. It began in 2021-07-01 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
Eligibility Criteria
Inclusion Criteria: * Emergency room presentation and/or hospitalization with COVID-19 infection defined in accordance with established criteria as follows: SAR-CoV2 RT-PCR+ (severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction) and at least one of the following symptoms: dyspnea, cough, dysphagia, rhinorrhea, diarrhea, nausea/vomiting, myalgias, fever, syncope/presyncope. Exclusion criteria: * Contraindication to CMR (i.e. non-compatible pacemaker/defibrillator) or gadolinium (known hypersensitivity, eGFR (estimated globular filtration rate) \<30 ml/min/1.73m2). * Inability to provide informed consent (e.g. cognitive impairment). * Unrelated condition (e.g. neoplasm) with life expectancy \<12 months prohibiting follow-up. * Patients with contraindications to gadolinium (known or suspected hypersensitivity, glomerular filtration rate \< 30 ml/min/1.73m2) will undergo non-contrast MRI but will not be excluded from this study. * Patients with known or suspected pregnancy based on Weill Cornell Radiology intake surveys (reviewed by a clinical RN (registered nurse), as well as research personnel) will be excluded from the protocol.
Contact & Investigator
Jiwon Kim, MD
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT05164744 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19 Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05164744 currently recruiting?
Yes, NCT05164744 is actively recruiting participants. Contact the research team at elm4036@med.cornell.edu for enrollment information.
Where is the NCT05164744 trial being conducted?
This trial is being conducted at Brooklyn, United States, New York, United States, New York, United States.
Who is sponsoring the NCT05164744 clinical trial?
NCT05164744 is sponsored by Weill Medical College of Cornell University. The principal investigator is Jiwon Kim, MD at Weill Medical College of Cornell University. The trial plans to enroll 510 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.